Correlation NKX2.2 IHC and < em > EWSR1 < /em > break-apart FISH in the diagnosis of Ewing sarcoma: Can combined NKX2.2 and CD99 immunoexpression obviate or minimize the need of FISH testing? First assessment study from Indian tertiary cancer care center
CONCLUSIONS: The presented study, which is the first from an Indian oncology center, showed NKX2.2 IHC is quite reliable in diagnosis of ES in the right clinicopathological context. With remarkable sensitivity and specificity of NKX2.2 IHC for diagnosis of ES, we propose that combined positivity of CD99 and NKX2.2 IHC can obviate or minimize the need of EWSR1 gene rearrangement molecular testing for diagnosis of ES.PMID:36656211 | DOI:10.4103/ijpm.ijpm_535_21 (Source: Indian Journal of Pathology and Microbiology)
Source: Indian Journal of Pathology and Microbiology - January 19, 2023 Category: Pathology Authors: Sunil Pasricha Saloni Pahwa Manish Pruthi Ankush Jajodia Gurudutt Gupta Anila Sharma Garima Durga Meenakshi Kamboj Akshay Tiwari Manoj Panigrahi Anurag Mehta Source Type: research
Correlation NKX2.2 IHC and < em > EWSR1 < /em > break-apart FISH in the diagnosis of Ewing sarcoma: Can combined NKX2.2 and CD99 immunoexpression obviate or minimize the need of FISH testing? First assessment study from Indian tertiary cancer care center
CONCLUSIONS: The presented study, which is the first from an Indian oncology center, showed NKX2.2 IHC is quite reliable in diagnosis of ES in the right clinicopathological context. With remarkable sensitivity and specificity of NKX2.2 IHC for diagnosis of ES, we propose that combined positivity of CD99 and NKX2.2 IHC can obviate or minimize the need of EWSR1 gene rearrangement molecular testing for diagnosis of ES.PMID:36656211 | DOI:10.4103/ijpm.ijpm_535_21 (Source: Indian Journal of Pathology and Microbiology)
Source: Indian Journal of Pathology and Microbiology - January 19, 2023 Category: Pathology Authors: Sunil Pasricha Saloni Pahwa Manish Pruthi Ankush Jajodia Gurudutt Gupta Anila Sharma Garima Durga Meenakshi Kamboj Akshay Tiwari Manoj Panigrahi Anurag Mehta Source Type: research
Correlation NKX2.2 IHC and < em > EWSR1 < /em > break-apart FISH in the diagnosis of Ewing sarcoma: Can combined NKX2.2 and CD99 immunoexpression obviate or minimize the need of FISH testing? First assessment study from Indian tertiary cancer care center
CONCLUSIONS: The presented study, which is the first from an Indian oncology center, showed NKX2.2 IHC is quite reliable in diagnosis of ES in the right clinicopathological context. With remarkable sensitivity and specificity of NKX2.2 IHC for diagnosis of ES, we propose that combined positivity of CD99 and NKX2.2 IHC can obviate or minimize the need of EWSR1 gene rearrangement molecular testing for diagnosis of ES.PMID:36656211 | DOI:10.4103/ijpm.ijpm_535_21 (Source: Indian Journal of Pathology and Microbiology)
Source: Indian Journal of Pathology and Microbiology - January 19, 2023 Category: Pathology Authors: Sunil Pasricha Saloni Pahwa Manish Pruthi Ankush Jajodia Gurudutt Gupta Anila Sharma Garima Durga Meenakshi Kamboj Akshay Tiwari Manoj Panigrahi Anurag Mehta Source Type: research
Extraskeletal mesenchymal chondrosarcoma of the distal thumb: A case report
CONCLUSION: EMCS is a highly malignant tumor with strong tendency of invasion and metastasis. Imaging is sometimes difficult to diagnose, and pathology is a necessary part of distinguishing between benign and malignant tumors. Operation is the major treatment to EMCS, meanwhile, adjuvant radiotherapy and chemotherapy also be effective. The overall prognosis is poor.PMID:36652820 | DOI:10.1016/j.ijscr.2023.107903 (Source: Hand Surgery)
Source: Hand Surgery - January 18, 2023 Category: Surgery Authors: Bin Chu Shifeng Jiang Quanqiu Sun Qi Chen Xin Peng Source Type: research
Molecular imaging of sarcomas with FDG PET
AbstractSarcoma comprises a heterogenous entity of musculoskeletal malignancies arising from a mesenchymal origin. The diagnosis and management of pediatric sarcoma requires a multidisciplinary approach and the use of various imaging modalities including CT, MRI and FDG PET scans. FDG PET/CT (FDG PET), as a metabolic imaging, complements and provides superior diagnostic information as against other imaging modalities alone. Advantages of FDG PET in differentiating malignant sarcomatous lesions from benign lesions, and value in staging and restaging have been noted in several studies. The use of FDG PET in clinical manageme...
Source: Skeletal Radiology - January 17, 2023 Category: Radiology Source Type: research
Periosteal chondrosarcoma: an unusual juxtacortical sarcoma
We report the case of a periosteal chondrosarcoma in a young woman, highlighting the diagnostic imaging features of this disease, and her treatment with a joint-sparing geometric resection of the distal femur, using patient-specific 3D-printed cutting guides and matched allograft reconstruction. (Source: Skeletal Radiology)
Source: Skeletal Radiology - January 17, 2023 Category: Radiology Source Type: research
Bone and soft tissue tumors at the borderlands of malignancy
AbstractThis review examines findings of musculoskeletal neoplasms whose equivocal imaging and/or histopathologic features make it difficult to determine if they will show aggressive behavior. We include both intermediate tumors as defined by the World Health Organization (WHO), and a single low-grade malignancy, low-grade central osteosarcoma, which mimics a benign lesion on imaging and histology. Intermediate tumors are a broad category and are subdivided into tumors that have risk of local recurrence only, and ones that have a risk of distant limb and pulmonary metastases. Difficult intermediate musculoskeletal lesions ...
Source: Skeletal Radiology - January 17, 2023 Category: Radiology Source Type: research
CORR Insights ®: Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model
Clin Orthop Relat Res. 2023 Jan 13. doi: 10.1097/CORR.0000000000002525. Online ahead of print.NO ABSTRACTPMID:36638387 | DOI:10.1097/CORR.0000000000002525 (Source: Clinical Orthopaedics and Related Research)
Source: Clinical Orthopaedics and Related Research - January 13, 2023 Category: Orthopaedics Authors: Adam S Levin Source Type: research
CORR Insights ®: Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model
Clin Orthop Relat Res. 2023 Jan 13. doi: 10.1097/CORR.0000000000002525. Online ahead of print.NO ABSTRACTPMID:36638387 | DOI:10.1097/CORR.0000000000002525 (Source: Cell Research)
Source: Cell Research - January 13, 2023 Category: Cytology Authors: Adam S Levin Source Type: research
CORR Insights ®: Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model
Clin Orthop Relat Res. 2023 Jan 13. doi: 10.1097/CORR.0000000000002525. Online ahead of print.NO ABSTRACTPMID:36638387 | DOI:10.1097/CORR.0000000000002525 (Source: Clinical Orthopaedics and Related Research)
Source: Clinical Orthopaedics and Related Research - January 13, 2023 Category: Orthopaedics Authors: Adam S Levin Source Type: research
CORR Insights ®: Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model
Clin Orthop Relat Res. 2023 Jan 13. doi: 10.1097/CORR.0000000000002525. Online ahead of print.NO ABSTRACTPMID:36638387 | DOI:10.1097/CORR.0000000000002525 (Source: Clinical Orthopaedics and Related Research)
Source: Clinical Orthopaedics and Related Research - January 13, 2023 Category: Orthopaedics Authors: Adam S Levin Source Type: research
CORR Insights ®: Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model
Clin Orthop Relat Res. 2023 Jan 13. doi: 10.1097/CORR.0000000000002525. Online ahead of print.NO ABSTRACTPMID:36638387 | DOI:10.1097/CORR.0000000000002525 (Source: Clinical Orthopaedics and Related Research)
Source: Clinical Orthopaedics and Related Research - January 13, 2023 Category: Orthopaedics Authors: Adam S Levin Source Type: research
A nonsteroidal anti-inflammatory drug, zaltoprofen, inhibits the growth of extraskeletal chondrosarcoma cells by inducing PPAR γ, p21, p27, and p53
. (Source: Cell Cycle)
Source: Cell Cycle - January 13, 2023 Category: Cytology Authors: Takashi Higuchi Akihiko Takeuchi Seiichi Munesue Norio Yamamoto Katsuhiro Hayashi Ai Harashima Yasuhiko Yamamoto Hiroyuki Tsuchiya Source Type: research
Intra-muscular extraskeletal myxoid chondrosarcoma of the thigh: a case report
Int J Clin Exp Pathol. 2022 Dec 15;15(12):476-479. eCollection 2022.ABSTRACTSoft tissue sarcomas are mesenchymal tumors that account for about 1% of all malignancies. We retrospectively analyzed a rare case of a painful intra-muscular extraskeletal myxoid chondrosarcoma in the thigh of a 35-year-old man, that had undergone excision. Histological and immunohistochemical analysis of the mass revealed extraskeletal myxoid chondrosarcoma. The patient proceeded to radiotherapy and chemotherapy after curative surgery and had a good outcome.PMID:36628074 | PMC:PMC9827227 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - January 11, 2023 Category: Pathology Authors: Hongli Xia Guoli Liu Ansen Wu Rong Zhao Shihuan Li Suqin Li Qiaofeng Zhou Zhi Zeng Ling Chen Mincai Li Source Type: research
Intra-muscular extraskeletal myxoid chondrosarcoma of the thigh: a case report
Int J Clin Exp Pathol. 2022 Dec 15;15(12):476-479. eCollection 2022.ABSTRACTSoft tissue sarcomas are mesenchymal tumors that account for about 1% of all malignancies. We retrospectively analyzed a rare case of a painful intra-muscular extraskeletal myxoid chondrosarcoma in the thigh of a 35-year-old man, that had undergone excision. Histological and immunohistochemical analysis of the mass revealed extraskeletal myxoid chondrosarcoma. The patient proceeded to radiotherapy and chemotherapy after curative surgery and had a good outcome.PMID:36628074 | PMC:PMC9827227 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - January 11, 2023 Category: Pathology Authors: Hongli Xia Guoli Liu Ansen Wu Rong Zhao Shihuan Li Suqin Li Qiaofeng Zhou Zhi Zeng Ling Chen Mincai Li Source Type: research
